Lantheus's radiodiagnostic is designed to identify cognitively impaired patients who have tau neurofibrillary tangle (NFT) pathology.

Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.

In the study, PF-07307405 showed efficacy of more than 70% in preventing Lyme disease. The vaccine candidate was found to be well tolerated with no identified safety concerns, acc ...

Infinimmune has raised $75m in Series A financing, helping the biotech advance its atopic dermatitis (AD)-centric pipeline. As part of the round, Infinimmune garnered the interest ...

Eli Lilly has lifted its full-year outlook for the second time this year on the back of another strong quarter, indicating it is far from relinquishing its dominant position as pace setter on the ...

Remepy has secured $36m in Series A funds to accelerate its pharmaceutical co-development partnerships and expand its hybrid drug pipeline.

The US FDA has granted breakthrough therapy designation to Lilly olomorasib as a potential treatment for adults with advanced pancreatic cancer who have already received at least one prior systemic ...

The FDA has granted accelerated approval to BMS' Zenbexus, along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma.

Jazz Pharmaceuticals is to acquire Actio Biosciences in a deal that includes an $820m upfront payment and up to $500m in additional contingent payments.

Epicrispr and Vaderis have secured $90m and $152m, respectively, to take their rare disease drugs to pivotal clinical development.

Eli Lilly is suing several US companies that are allegedly selling illegal versions of its weight loss candidate, retatrutide.

Armed with $95m in funding and a former Pfizer drug discovery specialist, Khartis Therapeutics has emerged with the aim of bringing a new treatment for an autoimmune disease that ...